Prion proteins leading to neurodegeneration

Current Alzheimer Research

Volumn 5, Issue 6, 2008, Pages 579-590

  Mendola, D L ^a   Pietropaolo, A ^b   Pappalardo, G ^a   Zannoni, C ^c   Rizzarelli, E ^b  

^a CNR   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Avian; Chicken; Copper affinity; Copper coordination environment; Molecular dynamics; Prion; SOD like activity

Indexed keywords

BINDING PROTEIN; COPPER BINDING PROTEIN; METAL ION; PRION PROTEIN; PROTEINASE K; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BETA SHEET; BIRD; CENTRAL NERVOUS SYSTEM; COPPER METABOLISM; ENZYME ACTIVITY; FISH; HUMAN; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REPTILE; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; CHICKENS; HUMANS; METALS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEURODEGENERATIVE DISEASES; PRIONS; PROTEIN CONFORMATION;

EID: 58149166855     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508786898415     Document Type: Review

References (158)

1. Dobson CM. Protein aggregation and its consequences for human disease. Protein Pept Lett 13: 219-227 (2006).
2. Westermark P. Aspects on human amyloid forms and their fibril polypeptides. FEBS J 272: 5942-5949 (2005).
3. Pepys MB. Amyloidosis. Annu Rev Med 57: 223-241(2006).
4. Bellotti V, Nuvolone M, Giorgetti S, Obici L, Palladini G, Russo P, et al. The workings of the amyloid diseases. Ann Med 39: 200-207 (2007).
5. Fandrich M. On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol Life Sci 64: 2066-2078 (2007).
6. Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66 (2 Suppl 1): S74-78 (2006).
7. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol 15: 3-16 (2004).
8. Harrison RS, Sharpe PC, Singh Y, Fairlie DP. Amyloid peptides and proteins in review. Rev Physiol Biochem Pharmacol 159: 1-77 (2007).
9. AigelsreiterA, Janig E, Stumptner C, Fuchsbichler A, Zatloukal K, Denk H, et al. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases. Pathobiology 74: 145-158 (2007).
10. Khare SD, Dokholyan NV. Molecular mechanisms of polypeptide aggregation in human diseases. Curr Protein Pept Sci 8: 573-579 (2007).
11. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med (10 Suppl): S10-S17 (2004).
12. Skovronsky DM, Lee VM, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1: 151-170 (2006).
13. Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis 4: 13-27 (2007).
14. Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31: 150-155 (2006).
15. Beyer K. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell Biochem Biophys 47: 285-299 (2007).
16. Shaw BF, Valentine JS. How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? Trends Biochem Sci 32: 78-85 (2007).
17. Stack EC, Ferrante RJ. Huntington's disease: progress and potential in the field. Expert Opin Investig Drugs 16: 1933-1953 (2007).
18. Aguzzi A, Heikenwalser M, Polymenidou M. Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 8: 552-561 (2007).
19. Bertram L, Tanzi RE. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545-555 (2005).
20. Ward M. Biomarkers for Alzheimer's disease. Expert Rev Mol Diagn 7: 635-646 (2007).
21. Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry 76: 906-919 (2005).
22. Colucci M, Moleres FJ, Xie ZL, Ray-Chaudhury A, Gutti S, Butefish CM, et al. Gerstmann- Straussler-Scheinker: a new phenotype with 'curly' PrP deposits. J Neuropathol Exp Neurol 65: 642-651 (2006).
23. Windl O, Dempster M, Estiberio JP, Lathe R, de Silva R, Esmonde T, et al. Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Hum Genet 98: 259-264 (1996).
24. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389: 498-501 (1997).
25. Caughey B, Baron GS. Prions and their partners in crime. Nature 443: 803-810 (2006).
26. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 113: 1250-1256 (2005).
27. Prusiner SB. Molecular biology and pathogenesis of prion diseases. Trends Biochem Sci 21: 482-487 (1996).
28. Pasternak SH, Callahan JW, Mahuran DJ. The role of the endosomal/ lysosomal system in amyloid-beta production and the pathophysiology of Alzheimer's disease: reexamining the spatial paradox from a lysosomal perspective. J Alzheimers Dis 6: 53-65 (2004).
29. DeMarco ML, Daggett V. Local environmental effects on the structure of the prion protein. CR Biologies 328: 847-862 (2005).
30. La Mendola D, Magrì A, Milardi D, Pappalardo G, Rizzarelli E. Environmental effects on conformational diseases. Reactive oxygen species and membrane interactions with prion, amylin and their peptide fragments. In: 'Recent Development in Bioinorganic Chemistry: Metal Complexes of Bioactive Molecules. (Ed: Saviano M.), Transworld Research Network, Kerala, p. 85-110 (2006).
31. Picotti P, De Franceschi G, Frare E, Spolaore B, Zambonin M, Chiti F, et al. Amyloid fibril formation and disaggregation of fragment 1-29 of apomyoglobin: insights into the effect of pH on protein fibrillogenesis. J Mol Biol 367: 1237-1245 (2007).
32. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146: 1041-1059 (2005).
33. Mrak RE, Griffin WS. Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol 66: 683-686 (2007).
34. Molina-Holgado F, Hider RC, Gaeta A, Williams R, Francis P. Metals ions and neurodegeneration. Biometals 20: 639-654 (2007).
35. Chiti F, Dobson CM. Protein misfolding and diseases. Ann Rev Biochem 75: 333-366 (2006).
36. Glabe CG. Common mechanism of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27: 570-575 (2006).
37. Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59: 332-345 (2007).
38. Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, Peng Z, et al. Metal exposure and Alzheimer's pathogenesis. J Struct Biol 155: 45-51 (2006).
39. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI, et al. Trace metal contamination initiates the apparent autoaggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J Biol Inorg Chem 9: 954-960 (2004).
40. Zatta P, Frank A. Copper deficiency and neurological disorders in man and animals. Brain Res Rev 54: 19-33 (2007).
41. Ong WY, Farooqui AA. Iron, neuroinflammation, and Alzheimer's disease. J Alzheimers Dis 8: 183-200 (2005).
42. Mocchegiani E, Bertoni-Freddari C, Marcellini F, Malavolta M. Brain, aging and neurodegeneration: role of zinc ion avalaibility. Prog Neurobiol 75: 367-390 (2005).
43. Tarohda T, Yamamoto M, Amamo R. Regional distribution of manganese, iron, copper, and zinc in the rat brain during development. Anal Bioanal Chem 380: 240-246 (2004).
44. Jackson B, Harper S, Smith L, Flinn J. Elemental mapping and quantitative analysis of Cu, Zn and Fe in rat brain sections by laser ablation ICP-MS. Anal Bioanal Chem 384: 951-957 (2006).
45. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 277: 44670-44676 (2002).
46. Adlard PA, Bush AI. Metals and Alzheimer's disease. J Alzheimers Dis 10: 145-163 (2006).
47. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52 (1998).
48. Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 1768: 1976-1990 (2007).
49. Shivers BD, Hilbich C, Multhaup G, Salbaum M, Beyreuther K, Seeburg PH, et al. Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. EMBO J 7: 1365-1370 (1988).
50. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273: 12817-12826 (1998).
51. Liu ST, Howlett G, Barrow CJ. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the Abeta peptide of Alzheimer's disease. Biochemistry 38: 9373-9378 (1999).
52. Shen L, Ji HF. Rat's trick to escape Alzheimer's disease. J Biomol Struct Dyn 25: 271-274 (2007).
53. Wopfner F, Weidenhofer G, Schneider R, von Brunn A, Gilch S, Schwarz TF, et al. Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. J Mol Biol 289: 1163-1178 (1999).
54. van Rheede T, Smolenaars MMW, Madsen O, de Jong WW. Molecular evolution of the mammalian prion protein. Mol Biol Evol 20: 111-121 (2003).
55. Harris DA, Falls DL, Johnson FA, Fischbach GD. A prion-like protein from chicken brain copurifies with an acetylcholine receptor-inducing activity. Proc Natl Acad Sci USA 88: 7664-7668 (1991).
56. Gabriel JM, Oesch B, Kretzschamer H, Scott M, Prusiner SB. Molecular cloning of a candidate chicken prion protein. Proc Natl Acad Sci USA 89: 9097-90101 (1992).
57. Simonic T, Duga S, Strumbo B, Asselta R, Ceciliani F, Ronchi S, et al. cDNA cloning of turtle prion protein. FEBS Lett 469: 33-38 (2000).
58. Strumbo B, Ronchi S, Bolis LC, Simonic T. Molecular cloning of the cDNA coding for Xenopus laevis prion protein. FEBS Lett 508: 170-174 (2001).
59. Suzuki T, Kurokawa T, Hashimoto H, Sugiyama M. cDNA sequence and tissue expression of Fugu rubripes prion protein-like: a candidate for the teleost orthologue of tetrapod PrPs. Biochem Biophys Res Commun 294: 912-917 (2002).
60. Stahl N, Prusiner SB. Prions and prion proteins. FASEB J 5: 2799-2807 (1991).
61. Prusiner SB. Prions, Nobel Lecture. Proc Natl Acad Sci USA 95: 13363-13383 (1998).
62. Horiuchi M, Yamazaki N, Ikeda T, Ishiguro N, Shinagawa M. A cellular form of prion protein (PrPC) exists in many non-neuronal tissues of sheep. J Gen Virol 76: 2583-2587 (1995).
63. Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, Burlingame AL, et al. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 32: 1991-2002 (1993).
64. Zou WQ, Gambetti P. Prion: the chameleon protein. Cell Mol Life Sci 64: 3266-3270 (2007).
65. Bueler H, Fisher M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356: 577-582 (1992).
66. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, et al. Normal host prion protein necessary for scrapieinduced neurotoxicity. Nature 379: 339-343 (1996).
67. Rochet JC, Lansbury P Jr. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10: 60-68 (2000).
68. Brown DR, Clive C, Haswell SJ. Antioxidant activity related to copper binding of native prion protein. J Neurochem 76: 69-76 (2001).
69. Chiesa R, Drisaldi B, Quaglio E, Migheli A, Piccardo P, Ghetti B, et al. Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation. Proc Natl Acad Sci USA 97: 5574-5579 (2000).
70. Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, et al. Signal transduction through prion protein. Science 289: 1925-1928 (2000).
71. Herms J, Tings T, Gall S, Madlung A, Giese A, Siebert H, et al. Evidence of presynaptic location and function of the prion protein. J Neurosci 19: 8866-8875 (1999).
72. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, et al. The cellular prion protein binds copper in vivo. Nature 390: 684-687 (1997).
73. Prado MA, Alves-Silva J, Magalhães AC, Prado VF, Linden R, Martins VR, et al. PrPC on the road: trafficking of the cellular prion protein. J Neurochem 88: 769-781 (2004).
74. Marcotte EM, Pellegrini M, Yeates TO, Eisenberg D. A census of protein repeats. J Mol Biol 293: 151-160 (1998).
75. Calzolai L, Lysek DA, Perez DR, Guntert P, Wüthrich K. Prion protein NMR structures of chickens, turtles, and frogs. Proc Natl Acad Sci USA 102: 651-655 (2005).
76. Marcotte EM, Eisemberg D. Chicken prion tandem repeats form a stable, protease resistant domain. Biochemistry 38: 667-676 (1999).
77. Ravi Chandra B, Gowthaman R, Raj Akhouri R, Gupta D, Sharma A. Distribution of proline- rich (PxxP) motifs in distinct proteomes: functional and therapeutic implications for malaria and tuberculosis. Protein Eng Des Sel 17: 175-182 (2004).
78. Lysek DA, Wuthrich K. Prion protein interaction with the C-terminal SH3 domain of Grb2 studied using NMR and optical spectroscopy. Biochemistry 43: 10393-10399 (2004).
79. Nunziante M, Gilch S, Schätzl HM. Essential role of the prion protein N-terminus in subcellular trafficking and half-life of cellular prion protein. J Biol Chem 278: 3726-3734 (2003).
80. Frankenfield KN, Powers ET, Kelly JW. Influence of the N-terminal domain on the aggregation properties of the prion protein. Protein Sci 14: 2154-2166 (2005).
81. Butowt R, Davies P, Brown DR. Anterograde axonal transport of chicken cellular prion protein (PrPc) in vivo requires its N-terminal part. J Neurosci Res 85: 2567-2579 (2007).
82. Shyng SL, Moulder KL, Lesko A, Harris DA. The N-terminal domain of a glycolipid-anchored prion protein is essential for its endocytosis via clathrin-coated pits. J Biol Chem 270: 14793-14800 (1995).
83. Pietropaolo A, Raiola L, Muccioli L, Tiberio G, Zannoni C, Fattorusso R, et al. An NMR and Molecular Dynamics investigation of the avian prion hexarepeat conformational features in solution. Chem Phys Lett 442: 110-118 (2007).
84. Pietropaolo A, Muccioli L, Zannoni C, La Mendola D, Maccarrone G, Pappalardo G, et al. Unveiling the role of histidine and tyrosine residues on the conformation of the avian prion hexarepeat domain. J Phys Chem B 112: 5182-5188 (2008).
85. Bansal A, Gierasch LM. The NPXY internalization signal of the LDL receptor adopts a reverse-turn conformation. Cell 67: 1195-1201 (1991).
86. Paccaud JP, Reith W, Johansson B, Magnusson KE, Mach B, Carpenter JL. Clathrin-coated pit-mediated receptor internalization. Role of internalization signals and receptor mobility. J Biol Chem 268: 23191-23196 (1993).
87. La Mendola D, Bonomo RP, Impellizzeri G, Maccarrone G, Pappalardo G, Rizzarelli E, et al. Copper(II) complexes with chicken prion repeats: influence of proline and tyrosine residues on the coordination features. J Biol Inorg Chem 10: 463-475 (2005).
88. Rivera-Milla E, Stuermer CA, Malaga-Trillo E. An evolutionary basis for scrapie disease: identification of a fish prion mRNA. Trends Genet 19: 72-75 (2003).
89. Pappalardo M, Milardi D, Grasso D, La Rosa C. Steered molecular dynamics studies reveal different unfolding pathways of prions from mammalian and non-mammalian species. New J Chem 31: 901-905 (2007).
90. Ji HF, Zhang HY. A comparative molecular dynamics study on thermostability of human and chicken prion proteins. Biochem Biophys Res Comm 359: 790-794 (2007).
91. De Simone A, Dodson GG, Zagari A, Fraternali F. Water molecules as structural determinants among prions of low sequence identity. FEBS Lett 580: 2488-2494 (2006).
92. Pietropaolo A, Muccioli L, Zannoni C, Rizzarelli E. Conformational stiffness of the full chicken prion protein in solution and its differencies with respect to mammals. submitted (2008).
93. C to fom β-sheet using NMR structures and sequence alignments. Biochem J 83: 1268-1280 (2002).
94. Pappalardo M, Milardi D, La Rosa C, Zannoni C, Grasso D, Rizzarelli E, et al. Molecular dynamics study on the conformational stability of 180-193 prion second helix fragment.Chem Phys Lett 390: 511-516 (2004).
95. George RA, Heringa J. An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng 15: 871-879 (2003).
96. Barducci A, Chelli R, Procacci P, Schettino V, Gervasio FL, Parrinello M, et al. Metadynamics simulation of prion protein: betastructure stability and the early stages of misfolding. J Am Chem Soc 128: 2705-2710 (2006).
97. Crichton RR, Pierre JL. Old iron, young copper: from Mars to Venus. Biometals 14: 99-112 (2001).
98. MacPherson IS, Murphy ME. Type-2 copper-containing enzymes. Cell Mol Life Sci 64: 2887-2899 (2007).
99. Bertinato J, L'Abbe MR. Maintaining copper homeostasis: regulation of copper-trafficking proteins in response to copper deficiency or overload. J Nutr Biochem 15: 316-322 (2004).
100. Bayer TA, Schafer S, Breyhan H, Wirths O, Treiber C, Multhaup G, et al. A vicious circle: role of oxidative stress, intraneuronal Abeta and Cu in Alzheimer's disease. Clin Neuropathol 25: 163-171 (2006).
101. Brown DR. Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathol 43: 229-243 (2005).
102. Milhavet O, Lehmann S. Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Res Brain Res Rev 38: 328-339 (2002).
103. Kim JI, Choi SI, Kim NH, Jin JK, Choi EK, Carp RI, et al. Oxidative stress and neurodegeneration in prion diseases. Ann N Y Acad Sci 928: 182-186 (2001).
104. Quaglio E, Chiesa R, Harris DA. Copper converts the cellular prion protein into a protease- resistant species that is distinct from the scrapie isoform. J Biol Chem 276: 11432-11438 (2001).
105. Brown DR. Copper and prion disease. Brain Res Bull 55: 165-173 (2001).
106. Westergard L, Christensen HM, Harris DA. The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 1772: 629-644 (2007).
107. Choi CJ, Kanthasamy A, Anantharam V, Kanthasamy AG. Interaction of metals with prion protein: possible role of divalent cations in the pathogenesis of prion diseases. Neurotoxicology 27: 777-787 (2006).
108. Brown DR, Sasson J. Copper-dependent functions for the prion protein. Mol Biotechnol 22: 165-178 (2002).
109. Vassallo N, Herms J. Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J Neurochem 86: 538-544 (2003).
110. Brown DR. Prion and prejudice: Normal protein and the synapse. Trends Neurosci 24: 85-90 (2001).
111. Perera WS, Hooper NM. Ablation of the metal ion-induced endocytosis of the prion protein by disease-associated mutation of the octarepeat region. Curr Biol 11: 519-523 (2001).
112. Taylor DR, Watt NT, Perera WS, Hooper NM. Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci 118: 5141-5153 (2005).
113. Pauly PC, Harris DA. Copper stimulates endocytosis of the prion protein. J Biol Chem 273: 33107-33110 (1998).
114. Brown DR, Besinger A. Prion protein expression and superoxide dismutase activity. Biochem J 334: 423-429 (1998).
115. Brown DR, Wong BS, Hafiz F, Clive C, Haswell SJ, Jones IM, et al. Normal prion protein has an activity like that of superoxide dismutase. Biochem J 344: 1-5 (1999).
116. Wong BS, Pan T, Liu T, Li R, Gambetti P, Sy MS, et al. Differential contribution of superoxide dismutase activity by prion protein in vivo. Biochem Biophys Res Commun 273: 136-139 (2000).
117. Hornshaw MP, McDermott JR, Candy JM. Copper binding to the N-terminal tandem repeat regions of mammalian and avian prion protein. Biochem Biophys Res Commun 207: 621-629 (1995).
118. Hornshaw MP, McDermott JR, Candy JM, Lakey JH. Copper binding to the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Biochem Biophys Res Commun 214: 993-999 (1995).
119. Millhauser GL. Copper binding in the prion protein. Acc Chem Res 37: 79-85 (2004).
120. Whittal RM, Ball HL, Cohen FE, Burlingame AL, Prusiner SB, Baldwin MA, et al. Copper binding to octarepeat peptides of the prion protein monitored by mass spectrometry. Protein Sci 9: 332-343 (2000).
121. Qin K, Yang Y, Mastrangelo P, Westaway D. Mapping Cu(II) binding sites in prion proteins by diethyl pyrocarbonate modification and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometric footprinting. J Biol Chem 277: 1981-1990 (2002).
122. Burns CS, Aronoff-Spencer E, Legname G, Prusiner SB, Antholine WE, Gerfen GJ, et al. Copper coordination in the full-length, recombinant prion protein. Biochemistry 42: 6794-6803 (2003).
123. Bonomo RP, La Mendola D, Pappalardo G, Rizzarelli E, Sovago I. Coordination features of prion protein domains. In: "Recent Development in Bioinorganic Chemistry: Metal Complexes of Bioactive Molecules", (Ed: Saviano M.), Transworld Research Network, Keralap, pp. 133-160 (2006).
124. Thompsett AR, Abdelraheim SR, Daniels M, Brown DR. High affinity binding between copper and full-length prion protein identified by two different techniques. J Biol Chem 280: 42750-42758 (2005).
125. Jackson GS, Murray I, Hosszu LL, Gibbs N, Waltho JP, Clarke AR, et al. Location and properties of metal-binding sites on the human prion protein. Proc Natl Acad Sci USA 98: 8531-85355 (2001
126. 2+ binding to His96 or His111 of the prion protein and spectroscopic evidence for a multiple histidine binding only at low pH. Biochem J 404: 393-402 (2007).
127. Osz K, Nagy Z, Pappalardo G, Di Natale G, Sanna D, Micera G, et al. Copper(II) interaction with prion peptide fragments encompassing histidine residues within and outside the octarepeat domain: speciation, stability constants and binding details. Chem Eur J 13: 7129-7143 (2007).
128. Chattopadhyay M, Walter ED, Newell DJ, Jackson PJ, Aronoff-Spencer E, Peisach J, et al. The octarepeat domain of the prion protein binds Cu(II) with three distinct coordination modes at pH 7.4. J Am Chem Soc 127: 12647-12656 (2005).
129. Burns CS, Aronoff-Spencer E, Dunham CM, Lario P, Avdievich NI, Olmstead MM, et al. Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry 41: 3991-4001 (2002).
130. Bonomo RP, Cucinotta V, Giuffrida A, Impellizzeri G, Magrì A, Pappalardo G, et al. A re- investigation of copper coordination in the octa-repeats region of the prion protein. Dalton Trans 150-158 (2005).
131. Walter ED, Chattopadhyay M, Millhauser GL. The affinity of copper binding to the prion protein octarepeat domain: evidence for negative cooperativity. Biochemistry 45: 13083- 13092 (2006).
132. Garnett AP, Viles JH. Copper binding to the octarepeats of the prion protein. Affinity, specificity, folding, and cooperativity: insights from circular dichroism. J Biol Chem 278: 6795-6802 (2003).
133. Stanczak P, Luczkowski M, Juszczyk P, Grzonka Z, Kozlowski H. Interactions of Cu2+ ions with chicken prion tandem repeats. Dalton Trans 2102-2107 (2004).
134. Stanczak P, Valensin D, Juszczyk P, Grzonka Z, Migliorini C, Molteni E, et al. Structure and stability of the Cu(II) complexes with tandem repeats of the chicken prion. Biochemistry 44: 12940-12954 (2005).
135. Di Natale G, Grasso G, Impellizzeri G, La Mendola D, Micera G, Mihala N, et al. Copper(II) interaction with unstructured prion domain outside the octarepeat region: speciation, stability, and binding details of copper(II) complexes with PrP106-126 peptides. Inorg Chem 44: 7214- 7225 (2005).
136. Joszai V, Nagy Z, Osz K, Sanna D, Di Natale G, La Mendola D, et al. Transition metal complexes of terminally protected peptides containing histidyl residues. J Inorg Biochem 100: 1399-1409 (2006).
137. Redecke L, Meyer-Klaucke W, Koker M, Clos J, Georgieva D, Genov N, et al. Comparative analysis of the human and chicken prion protein copper binding regions at pH 6.5. J Biol Chem 280:13987-13992 (2005).
138. Bataille M, Formicka-Kozlowska K, Kozlowski H, Pettit LD, Steel I. The L-proline residue as a break-point in the co-ordination of metal-peptide systems. J Chem Soc Chem Commun 4: 231-234 (1984)
139. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, et al. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43: 560-568 (2004).
140. La Mendola D, Bonomo RP, Carminati S, Di Natale G, Emmi SS, Hansson O, et al. Copper(II) complexes with avian prion N-terminal region and their potential SOD-like activity. submitted (2008).
141. Valensin D, Luczkowski M, Mancini FM, Legowska A, Gaggelli E, Valensin G, et al. The dimeric and tetrameric octarepeat fragments of prion protein behave differently to its monomeric unit. Dalton Trans 1284-1293 (2004).
142. Fioriti L, Quaglio E, Massignan T, Colombo L, Stewart RS, Salmona M, et al. The neurotoxicity of prion protein (PrP) peptide 106-126 is independent of the expression level of PrP and is not mediated by abnormal PrP species. Mol Cell Neurosci 28: 165-176 (2005).
143. Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I, et al. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 40: 8073-8084 (2001).
144. Kourie JI, Kenna BL, Tew D, Jobling MF, Curtain CC, Masters CL, et al. Copper modulation of ion channels of PrP [106-126] mutant prion peptide fragments. J Membr Biol 193: 35-45 (2003).
145. 2+ ions in affecting the interaction of prion peptide PrP106-126 with model membranes. Chem Commun 246-247 (2004)
146. 2+ coordination by His96 and His111 induces β-sheet formation in the unstructured amyloidogenic region of the prion protein. J Biol Chem 279: 32018-32027 (2004).
147. 2+ coordination modes. J Am Chem Soc 129: 15440-15441 (2007).
148. Brown DR, Schulz-Schaeffer WJ, Schmidt B, Kretzschmar HA. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp Neurol 146:104-112 (1997).
149. Brown DR, Hafiz F, Glasssmith LL, Wong BS, Jones IM, Clive C, et al. Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J 19: 1180-1186 (2000).
150. Stanczak P, Kozlowski H. Can chicken and human PrPs possess SOD-like activity after beta- cleavage? Biochem Biophys Res Commun 352: 198-202 (2007).
151. Stanczak P, Juszczyk P, Grzonka Z, Kozlowski H. The whole hexapeptide repeats domain from avian PrP displays untypical hallmarks in aspect of the Cu2+ complexes formation. FEBS Lett 581: 4544-4548 (2007).
152. Hutter G, Heppner FL, Aguzzi A. No superoxide dismutase activity of cellular prion protein in vivo. Biol Chem 384: 1279-1285 (2003).
153. Jones S, Batchelor M, Bhelt D, Clarke AR, Collinge J, Jackson GS, et al. Recombinant prion protein does not possess SOD-1 activity. Biochem J 392: 309-312 (2005).
154. Weinstein J, Bielski BHJ. Reaction of superoxide radicals with copper(II)-histidine complexes. J Am Chem Soc 102: 4916-4919 (1980).
155. Goldstein S, Czapski G, Meyerstein D. A mechanistic study of the copper(II)-peptide catalyzed superoxide dismutation. A pulse radiolysis study. J Am Chem Soc 112: 6489-6492 (1990).
156. Bonomo RP, Bruno V, Conte E, De Guidi G, La Mendola D, Maccarrone G, et al. Potentiometric, spectroscopic and biological activity studies of SOD mimics containing carnosine. Dalton Trans 4406-4415 (2003).
157. Treiber C, Pipkorn R, Weise C, Holland G, Multhaup G. Copper is required for prion protein- associated superoxide dismutase-1 activity in Pichia pastoris. FEBS J 274: 1304-1317 (2007).
158. Davies P, Brown DR. The chemistry of copper binding to PrP: Is there sufficient evidence to elucidate a role for copper in protein function? Biochem J 410: 237-244 (2008).